ARS Pharmaceuticals, Inc

Stason Pharmaceuticals is a US-based pharmaceutical company headquartered in Irvine, California, specializing in the development of partnerships and drugs within oncology, renal, and orphan indications. With its contract service divisions, MPhS and Western PharmSci, the company provides comprehensive contract packaging, analytical testing, and CDMO services to drug-development companies, supporting both clinical trial materials and commercial production of high-potency products. Since entering the US generic market in 1994, Stason has established a diverse portfolio and a global network of distributors. The company combines its advanced manufacturing capabilities, including high containment facilities, with strategic alliances across the US, Canada, Europe, and Asia to foster innovation and ensure compliance with industry standards. Generated from the website

ACADIA Pharmaceuticals is a biopharmaceutical company utilizing technology to fuel drug discovery and clinical development of treatments for central nervous system disorders. It has five drug programs in clinical and pre-clinical development directed at large unmet medical needs and major commercial markets. ACADIA s three Phase II-stage clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, ACP-103 as an adjunctive therapy for schizophrenia and ACP-104 for treatment of schizophrenia. The company also has clinical and pre-clinical development programs in the areas of neuropathic pain and glaucoma in collaboration with Allergan. ACADIA maintains headquarters and biology research facilities in San Diego and a chemistry research facility in Malmo, Sweden. It trades on NASDAQ under the symbol ACAD.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA, dedicated to developing innovative oral therapies for patients suffering from autoimmune inflammatory and neurodegenerative diseases. Leveraging expertise in medicinal chemistry, structural biology, and immunology, Ventyx aims to create differentiated small molecule therapeutics for conditions with significant unmet medical needs. The company's lead portfolio includes NLRP3 inhibitors such as VTX2735 and VTX3232, both in Phase 2 development for various diseases, alongside candidates for inflammatory bowel disease like tamuzimod and VTX958, which have completed Phase 2 trials. Ventyx is committed to advancing its drug candidates through clinical trials to improve patient outcomes. Generated from the website